title: Omalizumab for drug allergy.
authors.forename: Victor
authors.initials: V
authors.lastname: Matheu
authors.forename: Andres
authors.initials: A
authors.lastname: Franco
authors.forename: Eva
authors.initials: E
authors.lastname: Perez
authors.forename: Marta
authors.initials: M
authors.lastname: Hernández
authors.forename: Yvelise
authors.initials: Y
authors.lastname: Barrios
mesh_terms: D000328:Adult; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003888:Desensitization, Immunologic; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D004342:Drug Hypersensitivity / Q000150:complications / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007073:Immunoglobulin E / Q000096:biosynthesis; D007328:Insulin / Q000009:adverse effects / Q000276:immunology; D008297:Male; D000069444:Omalizumab
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007328:Insulin; D000069444:Omalizumab; D007073:Immunoglobulin E